Abstract | BACKGROUND: The spectrum of diseases that constitute the CD30+ lymphomas, with lymphomatoid papulosis (LyP) at one end, and anaplastic large-cell lymphoma (ALCL) at the other end, shows variable morphology, immunophenotype, and clinical behavior. The border between these diseases is sometimes difficult to establish and there are many grey zones in their classification. METHODS: We reviewed the clinical and research literature and guided by our experiences attempted to discern molecular and phenotypic criteria to improve the classification and identify molecular targets for therapy of CD30-positive cutaneous lymphomas. RESULTS: CONCLUSIONS: The current clinicopathologic classification of CD30+ cutaneous lymphoproliferative disorders is insufficient. Incorporating genetic and molecular criteria would better define the borders between benign/ malignant and aggressive/nonaggressive disorders.
|
Authors | Claudia Droc, Hernani D Cualing, Marshall E Kadin |
Journal | Cancer control : journal of the Moffitt Cancer Center
(Cancer Control)
Vol. 14
Issue 2
Pg. 124-32
(Apr 2007)
ISSN: 1073-2748 [Print] United States |
PMID | 17387297
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
|
Topics |
- Gene Expression
- Genes, bcl-2
- Humans
- Lymphoma, Large-Cell, Anaplastic
(classification, genetics, pathology)
- Molecular Biology
- Phenotype
- Prognosis
- Skin Neoplasms
(classification, genetics, pathology)
|